Neurological symptoms suggestive of demyelination in Crohn's disease after infliximab therapy.
Anti-TNFalpha drugs are currently used in the treatment of patients with Crohn's disease. Studies have reported neurological side effects occurring after anti-TNFalpha treatment, including infliximab-induced complications.
Dubcenco
Elena
E
Division of Gastroenterology, St. Michael's Hospital, Toronto, Ontario, Canada.
Ottaway
Clifford A
CA
Chen
Dean L
DL
Baker
Jeffrey P
JP
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D003424:Crohn Disease / Q000188:drug therapy*; D003711:Demyelinating Diseases / Q000139:chemically induced*; D005765:Gastrointestinal Agents / Q000009:adverse effects*; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab